Home › Compare › TBPMF vs JNJ

TBPMF vs JNJ: Dividend Comparison 2026

TBPMF yields 222222.22% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBPMF wins by $1.4076447531278624e+30M in total portfolio value
10 years
TBPMF
TBPMF
● Live price
222222.22%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4076447531278624e+30M
Annual income
$1,406,399,782,569,334,400,000,000,000,000,000,000.00
Full TBPMF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TBPMF vs JNJ

📍 TBPMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBPMFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBPMF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TBPMF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBPMF
Annual income on $10K today (after 15% tax)
$18,888,888.89/yr
After 10yr DRIP, annual income (after tax)
$1,195,439,815,183,934,200,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, TBPMF beats the other by $1,195,439,815,183,934,200,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBPMF + JNJ for your $10,000?

TBPMF: 50%JNJ: 50%
100% JNJ50/50100% TBPMF
Portfolio after 10yr
$7.038223765639312e+29M
Annual income
$703,199,891,284,667,200,000,000,000,000,000,000.00/yr
Blended yield
99.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TBPMF
No analyst data
Altman Z
-75.5
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBPMF buys
0
JNJ buys
0
No recent congressional trades found for TBPMF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBPMFJNJ
Forward yield222222.22% ✓2.13%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$1.4076447531278624e+30M$30.3K ✓
Annual income after 10y$1,406,399,782,569,334,400,000,000,000,000,000,000.00 ✓$4,689.40
Total dividends collected$1.4075632434891558e+30M$15.4K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TBPMF vs JNJ ($10,000, DRIP)

YearTBPMF PortfolioTBPMF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$22,232,922$22,222,222.22$10,592$272.30+$22.22M → TBPMF
2$46,198,082,523$46,174,293,296.41$11,289$357.73+$46198.07M → TBPMF
3$89,718,752,943,223$89,669,320,994,923.30$12,123$472.89+$89718752.93M → TBPMF
4$162,845,393,609,755,680$162,749,394,544,106,430.00$13,141$629.86+$162845393609.74M → TBPMF
5$276,249,735,879,778,500,000$276,075,491,308,616,120,000.00$14,408$846.81+$276249735879778.50M → TBPMF
6$437,989,462,258,048,500,000,000$437,693,875,040,657,100,000,000.00$16,021$1,151.60+$437989462258048512.00M → TBPMF
7$649,026,142,700,674,900,000,000,000$648,557,493,976,058,700,000,000,000.00$18,122$1,588.22+$649026142700674875392.00M → TBPMF
8$898,874,153,179,794,200,000,000,000,000$898,179,695,207,104,400,000,000,000,000.00$20,930$2,228.20+$8.988741531797941e+23M → TBPMF
9$1,163,523,886,474,633,300,000,000,000,000,000$1,162,562,091,130,731,000,000,000,000,000,000.00$24,792$3,191.91+$1.1635238864746333e+27M → TBPMF
10$1,407,644,753,127,862,300,000,000,000,000,000,000$1,406,399,782,569,334,400,000,000,000,000,000,000.00$30,274$4,689.40+$1.4076447531278624e+30M → TBPMF

TBPMF vs JNJ: Complete Analysis 2026

TBPMF — Stock

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

Full TBPMF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TBPMF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBPMF vs SCHDTBPMF vs JEPITBPMF vs OTBPMF vs KOTBPMF vs MAINTBPMF vs ABBVTBPMF vs MRKTBPMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.